Legal & General Group’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $873M | Sell |
1,955,764
-14,341
| -0.7% | -$6.69M | 0.2% | 91 |
|
|
2025
Q4 | $893M | Buy |
1,970,105
+17,808
| +0.9% | +$7.68M | 0.2% | 96 |
|
|
2025
Q3 | $765M | Buy |
1,952,297
+62,520
| +3% | +$26.1M | 0.17% | 107 |
|
|
2025
Q2 | $841M | Sell |
1,889,777
-4,392
| -0.2% | -$2.02M | 0.21% | 89 |
|
|
2025
Q1 | $918M | Buy |
1,894,169
+10,016
| +0.5% | +$4.67M | 0.25% | 74 |
|
|
2024
Q4 | $759M | Sell |
1,884,153
-21,159
| -1% | -$9.81M | 0.2% | 86 |
|
|
2024
Q3 | $886M | Sell |
1,905,312
-67,063
| -3% | -$32.2M | 0.23% | 73 |
|
|
2024
Q2 | $924M | Sell |
1,972,375
-53,291
| -3% | -$23.1M | 0.26% | 62 |
|
|
2024
Q1 | $847M | Sell |
2,025,666
-35,939
| -2% | -$15.2M | 0.24% | 73 |
|
|
2023
Q4 | $839M | Buy |
2,061,605
+21,247
| +1% | +$7.85M | 0.26% | 68 |
|
|
2023
Q3 | $710M | Sell |
2,040,358
-88,561
| -4% | -$31M | 0.25% | 72 |
|
|
2023
Q2 | $749M | Buy |
2,128,919
+42,588
| +2% | +$14.3M | 0.24% | 77 |
|
|
2023
Q1 | $657M | Buy |
2,086,331
+52,967
| +3% | +$15.9M | 0.24% | 88 |
|
|
2022
Q4 | $587M | Sell |
2,033,364
-104,734
| -5% | -$31.9M | 0.23% | 98 |
|
|
2022
Q3 | $619M | Sell |
2,138,098
-62,651
| -3% | -$18M | 0.24% | 83 |
|
|
2022
Q2 | $620M | Buy |
2,200,749
+143,620
| +7% | +$38.4M | 0.22% | 94 |
|
|
2022
Q1 | $537M | Buy |
2,057,129
+158,485
| +8% | +$37.6M | 0.16% | 124 |
|
|
2021
Q4 | $417M | Sell |
1,898,644
-169,690
| -8% | -$33M | 0.13% | 176 |
|
|
2021
Q3 | $375M | Buy |
2,068,334
+119,277
| +6% | +$23.3M | 0.12% | 180 |
|
|
2021
Q2 | $393M | Buy |
1,949,057
+240,660
| +14% | +$50.3M | 0.13% | 166 |
|
|
2021
Q1 | $367M | Sell |
1,708,397
-11,931
| -0.7% | -$2.62M | 0.14% | 162 |
|
|
2020
Q4 | $407M | Buy |
1,720,328
+34,424
| +2% | +$7.9M | 0.16% | 134 |
|
|
2020
Q3 | $459M | Buy |
1,685,904
+47,162
| +3% | +$13M | 0.21% | 96 |
|
|
2020
Q2 | $476M | Buy |
1,638,742
+53,940
| +3% | +$14.6M | 0.23% | 81 |
|
|
2020
Q1 | $377M | Buy |
1,584,802
+66,406
| +4% | +$15.2M | 0.22% | 96 |
|
|
2019
Q4 | $332M | Buy |
1,518,396
+55,481
| +4% | +$11.2M | 0.16% | 139 |
|
|
2019
Q3 | $248M | Buy |
1,462,915
+3,297
| +0.2% | +$583K | 0.13% | 195 |
|
|
2019
Q2 | $268M | Buy |
1,459,618
+8,308
| +0.6% | +$1.45M | 0.14% | 165 |
|
|
2019
Q1 | $267M | Buy |
1,451,310
+297,731
| +26% | +$55M | 0.15% | 153 |
|
|
2018
Q4 | $191M | Buy |
1,153,579
+79,216
| +7% | +$13.7M | 0.15% | 160 |
|
|
2018
Q3 | $207M | Buy |
1,074,363
+20,630
| +2% | +$3.67M | 0.15% | 159 |
|
|
2018
Q2 | $179M | Sell |
1,053,733
-43,434
| -4% | -$6.73M | 0.14% | 176 |
|
|
2018
Q1 | $179M | Sell |
1,097,167
-53,915
| -5% | -$8.81M | 0.14% | 176 |
|
|
2017
Q4 | $173M | Sell |
1,151,082
-26,186
| -2% | -$3.88M | 0.12% | 192 |
|
|
2017
Q3 | $179M | Buy |
1,177,268
+36,305
| +3% | +$5.46M | 0.13% | 186 |
|
|
2017
Q2 | $147M | Buy |
1,140,963
+53,020
| +5% | +$6.38M | 0.12% | 204 |
|
|
2017
Q1 | $119M | Buy |
1,087,943
+39,469
| +4% | +$3.47M | 0.1% | 230 |
|
|
2016
Q4 | $77.2M | Buy |
1,048,474
+10,839
| +1% | +$882K | 0.07% | 302 |
|
|
2016
Q3 | $90.5M | Buy |
1,037,635
+10,690
| +1% | +$1.01M | 0.09% | 248 |
|
|
2016
Q2 | $88.3M | Buy |
1,026,945
+50,584
| +5% | +$4.37M | 0.09% | 252 |
|
|
2016
Q1 | $77.6M | Sell |
976,361
-81
| -0% | -$7.33K | 0.09% | 261 |
|
|
2015
Q4 | $123M | Buy |
976,442
+7,091
| +0.7% | +$856K | 0.14% | 167 |
|
|
2015
Q3 | $101M | Buy |
969,351
+33,959
| +4% | +$4.36M | 0.12% | 195 |
|
|
2015
Q2 | $116M | Buy |
935,392
+21,679
| +2% | +$2.73M | 0.14% | 182 |
|
|
2015
Q1 | $108M | Sell |
913,713
-1,536
| -0.2% | -$184K | 0.13% | 193 |
|
|
2014
Q4 | $109M | Sell |
915,249
-21,681
| -2% | -$2.44M | 0.13% | 198 |
|
|
2014
Q3 | $105M | Sell |
936,930
-52,935
| -5% | -$5.04M | 0.13% | 193 |
|
|
2014
Q2 | $93.7M | Buy |
989,865
+23,257
| +2% | +$1.63M | 0.11% | 225 |
|
|
2014
Q1 | $68.4M | Sell |
966,608
-4,721
| -0.5% | -$374K | 0.08% | 270 |
|
|
2013
Q4 | $72.2M | Buy |
971,329
+35,123
| +4% | +$2.45M | 0.09% | 257 |
|
|
2013
Q3 | $71M | Buy |
936,206
+64,367
| +7% | +$5.12M | 0.09% | 248 |
|
|
2013
Q2 | $69.6M | Buy |
+871,839
| New | +$64.2M | 0.1% | 242 |
|
Other funds holding VRTX
VCM
VPM
Legal & General Group's VRTX Position: Q1 2026 in Review
Legal & General Group reduced its Vertex Pharmaceuticals (VRTX) stake by 0.73% in Q1 2026, selling an estimated $6.69M and leaving 1,955,764 shares worth $873M. The position accounts for 0.2% of the portfolio, ranked #91.
Legal & General Group first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $924M in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Legal & General Group held 1,955,764 shares of Vertex Pharmaceuticals worth $873M as of Q1 2026.
- Legal & General Group sold 14,341 Vertex Pharmaceuticals shares in Q1 2026, an estimated $6.69M.
- Vertex Pharmaceuticals made up 0.2% of Legal & General Group's portfolio in Q1 2026, its #91 holding.
- Legal & General Group first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Legal & General Group's Vertex Pharmaceuticals position peaked at $924M in Q2 2024.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.